The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

Stefan Flasche*, Albert Jan Van Hoek, David Goldblatt, W. John Edmunds, Katherine L. O’Brien, J. Anthony G. Scott, Elizabeth Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)
Original languageEnglish
Article numbere1001839
JournalPLoS Medicine
Issue number6
Publication statusPublished - 1 Jun 2015

Bibliographical note

Funding Information:
I have read the journal's policy and have the following conflicts: KLOB has research funding related to pneumococcal vaccine from National Institutes of Health, Glaxosmithkline, Pfizer, the Bill & Melinda Gates Foundation, and Gavi, The Vaccine Alliance. DG’s laboratory is in receipt of collaborative and/or contract funding from vaccine manufacturers including Merck, Sanofi Pasteur, GSK, and Novartis, and DG has received honoraria or consulting fees in the past from Merck, GSK, Sanofi Pasteur, Novartis, and Pfizer. WJE’s partner works for GSK. JAGS is a member of the Joint Committee of Vaccination and Immunisation, has received financial support for research on pneumococcal vaccines from the Wellcome Trust, the National Institute for Health Research (UK), GAVI—the Vaccine Alliance, and PATH Vaccine Solutions, has done consultancy work on pneumococcal vaccines for PATH Vaccine Solutions, and received financial support for research by GSK in 2009/10. SF, AJVH and EM declare no conflict of interest.

Cite this